



NDA 202155/S-004

**SUPPLEMENT APPROVAL**

Bristol-Myers Squibb  
ATTENTION: Linda Gambone, Ph.D.  
Associate Director, Global Regulatory Sciences  
P.O. Box 4000  
Princeton, NJ 08543-4000

Dear Dr. Gambone:

Please refer to your Supplemental New Drug Application (sNDA) dated July 17, 2013, received July 17, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Eliquis (apixaban) 2.5 and 5 mg Tablets.

This Prior Approval supplemental new drug application provides new carton and container labels for a 2.5 mg physician sample and amended carton and container labels for the 5.0 mg physician sample.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text. As a reminder, please ensure that the lot number and expiration date are included on both the 2.5 mg and 5 mg professional sample carton labeling.

**CARTON AND IMMEDIATE CONTAINER LABELS**

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 202155/S-004.**” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call:

Alison Blaus, RAC  
Senior Regulatory Project Manager  
(301) 796-1138

Sincerely,

*{See appended electronic signature page}*

Norman Stockbridge, M.D., Ph.D.  
Director  
Division of Cardiovascular & Renal Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

ENCLOSURE:  
Carton and Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

NORMAN L STOCKBRIDGE  
10/31/2013